Evidence map›Paper›PMID 24625659›Full record

ArticlePloS one2014

Intravenous phosphate loading increases fibroblast growth factor 23 in uremic rats.

Noriko Arai-Nunota, Masahide Mizobuchi, Hiroaki Ogata, Ai Yamazaki-Nakazawa, Chiaki Kumata, Fumiko Kondo, Nozomu Hosaka, Fumihiko Koiwa, Eriko Kinugasa, Takanori Shibata and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Fibroblast Growth Factor 23 as Regulator of Vitamin D Metabolism.Advances in experimental medicine and biology · 2022
    Article
  2. Article
  3. How do we sense phosphate to regulate serum phosphate level?Journal of bone and mineral metabolism · 2020
    Review
  4. Article
  5. Review
  6. Multiple faces of fibroblast growth factor-23.Current opinion in nephrology and hypertension · 2016
    Review
  7. Article
  8. Functional diversity of fibroblast growth factors in bone formation.International journal of endocrinology · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Noriko Arai-NunotaDivision of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
Masahide MizobuchiDivision of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
Hiroaki OgataDepartment of Internal Medicine, Showa University Northern Yokohama Hospital, Yokohama, Japan.
Ai Yamazaki-NakazawaDivision of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
Chiaki KumataDepartment of Internal Medicine, Showa University Northern Yokohama Hospital, Yokohama, Japan.
Fumiko KondoDivision of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
Nozomu HosakaDivision of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
Fumihiko KoiwaDivision of Nephrology, Department of Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan.
Eriko KinugasaDepartment of Internal Medicine, Showa University Northern Yokohama Hospital, Yokohama, Japan.
Takanori ShibataDivision of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
Tadao AkizawaDivision of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
Showa University · JPShowa University Northern Yokohama Hospital · JPShowa University Fujigaoka Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oral phosphate loading and calcitriol stimulate Fibroblast growth factor 23 (FGF23) secretion, but the mechanisms underlying the stimulation of FGF23 remain to be studied. We compared the effect of intravenous phosphate loading with that of oral loading on FGF23 levels in normal and 5/6 nephrectomized uremic rats. Uremic rats (Nx) and sham-operated rats were fed a normal phosphate diet for 2 weeks and then divided into 3 groups: 1) with the same phosphate diet (NP), 2) with a high phosphate diet (HP), and 3) NP rats with intravenous phosphate infusion using a microinfusion pump (IV). Blood and urine were obtained 1 day (early phase) and 7 days (late phase) after the interventions. In the early and late phases, serum phosphate levels and fractional excretion of phosphate (FEP) were comparable in the HP and IV groups in both Sham and Nx rats. Serum phosphate levels in the HP and IV groups were equally and significantly higher than those in the NP group only in the late phase in Nx rats. In the early phase, FGF23 levels were comparable in the NP, HP, and IV groups, but were significantly higher in the HP and IV groups compared to the NP group in the late phase in Nx rats. 1α-hydroxylase and sodium dependent phosphate co-transporter 2a expression levels in the kidney in Nx rats were equally and significantly decreased in the HP and IV groups compared with the NP group, while 24-hydroxylase expression was equally and significantly increased. These results show that chronic intravenous phosphate loading increases bioactive FGF23, indicating that an alternative pathway for FGF23 regulation, in addition to the dietary route, may be present. This pathway is clearer under conditions produced by a kidney injury in which phosphate is easily overloaded.

Indexed as

AnimalsFibroblast Growth FactorsImmunohistochemistryInfusions, IntravenousMaleNephrectomyPhosphatesRatsRats, Sprague-DawleySodium-Phosphate Cotransporter Proteins, Type IIaUremiaVitamin D3 24-HydroxylaseFgf23 protein, ratFibroblast Growth FactorsPhosphatesSlc34a1 protein, ratSodium-Phosphate Cotransporter Proteins, Type IIaVitamin D3 24-Hydroxylase

Identifiers

PMID24625659
PMCPMC3953214
OpenAlexW2169838628

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.